分析员R. Daniels降低Astrana Health的2024财政年度EPS估计数,而其他分析家则保持购买评级。 Analyst R. Daniels lowers Astrana Health's FY2024 EPS estimate, while other analysts maintain buy ratings.
分析员R. Daniels将William Blair的Astrana Health(NASDAQ:ATTH)2024财政年度每股收入估计数从1.39美元降至1.18美元。 Analyst R. Daniels has lowered William Blair's FY2024 earnings per share (EPS) estimate for Astrana Health (NASDAQ: ASTH) from $1.39 to $1.18 per share. 尽管如此，包括Baird R W、Stifel Nicolaus、Robert W. Baird和Truist Financial在内的其他分析师已对该公司给予买入或强烈买入评级，该公司报告第三季度收益超出预期（每股收益为0.40美元，预期为0.39美元）。 Despite this, other analysts including Baird R W, Stifel Nicolaus, Robert W. Baird, and Truist Financial have assigned buy or strong buy ratings to the company, which reported a Q3 earnings beat ($0.40 EPS vs estimated $0.39). 凭借平均评分为"买入"和平均目标价格为55.75美元,Astrana Health作为一家以医生为中心的技术驱动的医疗管理公司,分为三大部门:护理合作伙伴,护理交付和护理启用. With an average rating of "Buy" and an average target price of $55.75, Astrana Health operates as a physician-centric technology-powered healthcare management company with three segments: Care Partners, Care Delivery, and Care Enablement.